H.R. 3884 would authorize the appropriation of $8 million each year from 2024 through 2028 for the Centers for Disease Control and Prevention and the Health Resources and Services Administration to conduct research, surveillance, prevention, and treatment of sickle cell disease and related blood disorders. (In 2023, $4 million was allocated for these purposes.) Based on historical spending patterns for those activities and assuming the appropriation of the authorized amounts, CBO estimates that implementing the bill would cost $37 million over the 2024-2028 period and $4 million after 2028.
